Estela Rodriguez: Updated analysis of CM816
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a recent article by Mark M. Awad et al. on X:
“Updated analysis of CM816 via Journal of Clinical Oncology.
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer in Journal of Clinical Oncology.
LCSM pCR 20% vs 4.6% 3 years OS 73% vs 61% (HR 0.73) favors neoadjuvant Ipilimumab plus Nivolumab.
- Increased ctDNA clearance in the chemotherapy arm.
- Increased survival in inflamed phenotype.”
“Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer“
Authors: Mark M. Awad, Patrick M. Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Stephen R. Broderick, Scott J. Swanson, Julie Brahmer, Keith Kerr, Gene B. Saylors, Ke-Neng Chen, Vishwanath Gharpure, Jaclyn Neely, David Balli and Mariano Provencio Pulla
Estela (Estelamari) Rodriguez is Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board-certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.
More posts featuring Estela Rodriguez.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023